PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF Russian patent published in 2020 - IPC C07D405/14 C07D403/04 C07D403/14 C07D413/14 C07D403/08 A61K31/506 A61K31/5377 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to compounds of general formula (I), stereoisomers or pharmaceutically acceptable salts thereof, where in formula (I) R₁ and R₂ each independently denotes H, C₁-C₈ alkyl, C₁-C₅ acyl, each of which is optionally substituted by at least one of halide, hydroxyl, C₁-C₅ alkoxy and C₃-C₆ heteroaryl, containing one or two nitrogen atoms in the ring optionally substituted with methyl; or R₁ and R₂ together with the nitrogen atom to which they are bonded, form 4–7-member saturated ring which optionally includes O, or 5-member aromatic ring, which contains N; R₃ denotes H or linear C₁-C₈ alkyl optionally substituted with hydroxyl; or R₁ or R₂ together with R₃ and a carbon atom and a nitrogen atom, with which each is bonded, form 5-member saturated ring, which optionally includes at least one of NH, O and C=O; R₄ and R₈ denote H; R₅ denotes a halide or C₁-C₈ alkyl optionally substituted with at least one halogenide; R₆ denotes C₁-C₈ alkyl, C₅-C₆ cycloalkyl or 4–6-member saturated heterocyclyl containing an oxygen atom in the ring; R₇ denotes C₁-C₈ alkyl substituted with C₃-C₇ cycloalkyl. Invention also relates to specific compounds specified in the patent claim, to methods of inhibiting and a method of treating malignant diseases.

(I)

EFFECT: technical result is pyrazolopyrimidine derivatives of formula (I) as inhibitors of casein kinase I (CKI) and kinase 1 associated with interleukin-1 receptor (IRAK1).

40 cl, 3 tbl, 42 dwg